Company news

Zevra Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

November 19, 2023

Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results

November 6, 2023

Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8: 00 a.m. ET

October 30, 2023

Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October

October 18, 2023

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

October 9, 2023

Zevra Therapeutics to Present at the 52nd Child Neurology Society Annual Meeting

October 4, 2023

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

October 1, 2023

Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference

September 19, 2023

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

September 8, 2023

Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

August 30, 2023

Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results

August 13, 2023

Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster

August 6, 2023

Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023

August 1, 2023

Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference

July 18, 2023

Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023

June 19, 2023

Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

June 12, 2023

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

June 2, 2023

Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results

May 14, 2023

Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

May 9, 2023

Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023

May 8, 2023

Zevra Announces Board of Directors and Leadership Changes

May 7, 2023

Zevra Therapeutics Announces FDA Acceptance of IND Application for KP1077 in Narcolepsy

May 2, 2023

Leading Proxy Advisory Firms ISS and Glass Lewis Demonstrate Strong Support for Zevra’s Transformation Strategy

April 16, 2023

Zevra Therapeutics Announces Submission of IND for KP1077 in Narcolepsy

April 3, 2023

Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors

March 29, 2023

Zevra Therapeutics Announces Collaboration with RARE-X and the Sleep Consortium as Founding Member of New Sleep Data Initiative

March 16, 2023

Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

March 14, 2023

Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates

March 6, 2023

Zevra Therapeutics to Present at 35th Annual Roth Conference

March 5, 2023

Zevra Therapeutics Begins Trading as ZVRA

February 28, 2023

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD)

February 27, 2023

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

February 26, 2023

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy

February 26, 2023

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023

February 23, 2023

Zevra Therapeutics Announces Two Abstracts Accepted for Presentation at the 19th Annual WORLDSymposium™ 2023

February 22, 2023

KemPharm Announces Corporate Name Change to Zevra Therapeutics

February 21, 2023

KemPharm Enhances Senior Management Team

January 30, 2023

KemPharm Issues Letter to Shareholders

January 23, 2023

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

January 17, 2023

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

January 10, 2023

KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

January 8, 2023

KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

December 20, 2022

KemPharm Announces Appointment of Christopher Posner as New Independent Director

November 28, 2022

KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

November 17, 2022

KemPharm Reports Third Quarter 2022 Results

November 8, 2022

KemPharm to Report Third Quarter 2022 Financial Results

October 31, 2022

KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

October 3, 2022

KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

September 27, 2022

KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 31, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 61 decks. Every deck is listed under its year.